Artificial intelligence (AI) pharmatech company, Exscientia, has announced a collaboration with Bristol Myers Squibb to accelerate the discovery of small molecule therapeutic drug candidates in multiple therapeutic areas, including oncology and immunology.
The agreement includes up to $50 million in upfront funding, up to $125 million in near to mid-term potential milestones, and additional clinical, regulatory, and commercial payments that take the potential value of the deal beyond $1.2 billion.